113 related articles for article (PubMed ID: 32440925)
41. Non-invasive prediction of IDH-wildtype genotype in gliomas using dynamic
Vettermann F; Suchorska B; Unterrainer M; Nelwan D; Forbrig R; Ruf V; Wenter V; Kreth FW; Herms J; Bartenstein P; Tonn JC; Albert NL
Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2581-2589. PubMed ID: 31410540
[TBL] [Abstract][Full Text] [Related]
42. miR-320a functions as a suppressor for gliomas by targeting SND1 and β-catenin, and predicts the prognosis of patients.
Li H; Yu L; Liu J; Bian X; Shi C; Sun C; Zhou X; Wen Y; Hua D; Zhao S; Ren L; An T; Luo W; Wang Q; Yu S
Oncotarget; 2017 Mar; 8(12):19723-19737. PubMed ID: 28160566
[TBL] [Abstract][Full Text] [Related]
43. Identifying Lesions of the Corpus Callosum in Patients With Neurofibromatosis Type 1.
Jandhyala NR; Garcia MR; Kim M; Yohay K; Segal D
Pediatr Neurol; 2024 Jul; 156():66-71. PubMed ID: 38733856
[TBL] [Abstract][Full Text] [Related]
44. Characterizing invading glioma cells based on IDH1-R132H and Ki-67 immunofluorescence.
Sabit H; Nakada M; Furuta T; Watanabe T; Hayashi Y; Sato H; Kato Y; Hamada J
Brain Tumor Pathol; 2014 Oct; 31(4):242-6. PubMed ID: 24384677
[TBL] [Abstract][Full Text] [Related]
45. Expression and prognostic value of JAM-A in gliomas.
Rosager AM; Sørensen MD; Dahlrot RH; Boldt HB; Hansen S; Lathia JD; Kristensen BW
J Neurooncol; 2017 Oct; 135(1):107-117. PubMed ID: 28677106
[TBL] [Abstract][Full Text] [Related]
46. KITENIN promotes glioma invasiveness and progression, associated with the induction of EMT and stemness markers.
Lee KH; Ahn EJ; Oh SJ; Kim O; Joo YE; Bae JA; Yoon S; Ryu HH; Jung S; Kim KK; Lee JH; Moon KS
Oncotarget; 2015 Feb; 6(5):3240-53. PubMed ID: 25605251
[TBL] [Abstract][Full Text] [Related]
47. Molecularly based management of gliomas in clinical practice.
Rudà R; Pellerino A; Magistrello M; Franchino F; Pinessi L; Soffietti R
Neurol Sci; 2015 Sep; 36(9):1551-7. PubMed ID: 26194534
[TBL] [Abstract][Full Text] [Related]
48. Prognostic value of ion channel genes in Chinese patients with gliomas based on mRNA expression profiling.
Lu FF; Wang HY; He XZ; Liang TY; Wang W; Hu HM; Wu F; Liu YW; Zhang SZ
J Neurooncol; 2017 Sep; 134(2):397-405. PubMed ID: 28752501
[TBL] [Abstract][Full Text] [Related]
49. MiRNA expression profiling in human gliomas: upregulated miR-363 increases cell survival and proliferation.
Conti A; Romeo SG; Cama A; La Torre D; Barresi V; Pezzino G; Tomasello C; Cardali S; Angileri FF; Polito F; Ferlazzo G; Di Giorgio R; Germanò A; Aguennouz M
Tumour Biol; 2016 Oct; 37(10):14035-14048. PubMed ID: 27495233
[TBL] [Abstract][Full Text] [Related]
50. Diffusion Tensor Imaging Shows Corpus Callosum Differences between High-Grade Gliomas and Metastases.
Cho NS; Jenabi M; Arevalo-Perez J; Brennan N; Young RJ; Karimi S; Holodny AI; Peck KK
J Neuroimaging; 2018 Mar; 28(2):199-205. PubMed ID: 29064137
[TBL] [Abstract][Full Text] [Related]
51. Molecular Biology in Pediatric High-Grade Glioma: Impact on Prognosis and Treatment.
Rizzo D; Ruggiero A; Martini M; Rizzo V; Maurizi P; Riccardi R
Biomed Res Int; 2015; 2015():215135. PubMed ID: 26448930
[TBL] [Abstract][Full Text] [Related]
52. miR-139 Functions as An Antioncomir to Repress Glioma Progression Through Targeting IGF-1 R, AMY-1, and PGC-1β.
Wang H; Yan X; Ji LY; Ji XT; Wang P; Guo SW; Li SZ
Technol Cancer Res Treat; 2017 Aug; 16(4):497-511. PubMed ID: 26868851
[TBL] [Abstract][Full Text] [Related]
53. Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas.
Puputti M; Tynninen O; Sihto H; Blom T; Mäenpää H; Isola J; Paetau A; Joensuu H; Nupponen NN
Mol Cancer Res; 2006 Dec; 4(12):927-34. PubMed ID: 17189383
[TBL] [Abstract][Full Text] [Related]
54. Characterizing temporal genomic heterogeneity in pediatric high-grade gliomas.
Salloum R; McConechy MK; Mikael LG; Fuller C; Drissi R; DeWire M; Nikbakht H; De Jay N; Yang X; Boue D; Chow LML; Finlay JL; Gayden T; Karamchandani J; Hummel TR; Olshefski R; Osorio DS; Stevenson C; Kleinman CL; Majewski J; Fouladi M; Jabado N
Acta Neuropathol Commun; 2017 Oct; 5(1):78. PubMed ID: 29084603
[TBL] [Abstract][Full Text] [Related]
55. The novel chromatin architectural regulator SND1 promotes glioma proliferation and invasion and predicts the prognosis of patients.
Yu L; Xu J; Liu J; Zhang H; Sun C; Wang Q; Shi C; Zhou X; Hua D; Luo W; Bian X; Yu S
Neuro Oncol; 2019 Jun; 21(6):742-754. PubMed ID: 30753603
[TBL] [Abstract][Full Text] [Related]
56. The molecular biology of WHO grade II gliomas.
Marko NF; Weil RJ
Neurosurg Focus; 2013 Feb; 34(2):E1. PubMed ID: 23373446
[TBL] [Abstract][Full Text] [Related]
57. miR-3175 and miR-134 affect proliferation, invasion and apoptosis of glioma cells through PI3K/AKT signaling pathway.
Qi A; Han J; Jia F; Liu C
J BUON; 2019; 24(6):2465-2474. PubMed ID: 31983121
[TBL] [Abstract][Full Text] [Related]
58. SOCS3 promoter methylation is mutually exclusive to EGFR amplification in gliomas and promotes glioma cell invasion through STAT3 and FAK activation.
Lindemann C; Hackmann O; Delic S; Schmidt N; Reifenberger G; Riemenschneider MJ
Acta Neuropathol; 2011 Aug; 122(2):241-51. PubMed ID: 21590492
[TBL] [Abstract][Full Text] [Related]
59. An NF-κB signature predicts low-grade glioma prognosis: a precision medicine approach based on patient-derived stem cells.
Ius T; Ciani Y; Ruaro ME; Isola M; Sorrentino M; Bulfoni M; Candotti V; Correcig C; Bourkoula E; Manini I; Pegolo E; Mangoni D; Marzinotto S; Radovic S; Toffoletto B; Caponnetto F; Zanello A; Mariuzzi L; Di Loreto C; Beltrami AP; Piazza S; Skrap M; Cesselli D
Neuro Oncol; 2018 May; 20(6):776-787. PubMed ID: 29228370
[TBL] [Abstract][Full Text] [Related]
60. DDX3X Biomarker Correlates with Poor Survival in Human Gliomas.
Hueng DY; Tsai WC; Chiou HY; Feng SW; Lin C; Li YF; Huang LC; Lin MH
Int J Mol Sci; 2015 Jul; 16(7):15578-91. PubMed ID: 26184164
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
